Pharmacy, Hospital Parc Taulí, Sabadell, Spain.
Biostatistics Unit. Facultat de Medicina, Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Vallés), Spain.
Eur J Hosp Pharm. 2021 Jan;28(1):28-32. doi: 10.1136/ejhpharm-2019-001893. Epub 2019 May 20.
To describe the association between exposure to different antidepressant drugs and hip fracture in an elderly Mediterranean population.
Cases were all patients aged 50-95 years admitted to the emergency room of our hospital with hip fracture not related to a high intensity trauma during 2010. For each case, four controls were identified from primary care electronic medical records matched by age (±3 years), gender, date of consultation at the primary care centre (±1 month) and primary care centre. Pharmacological treatments received within the previous 5 years were retrieved from the prescription records. Crude and adjusted risks associated with exposures were calculated by conditional logistic regression. ORs were adjusted by matching variables and by significant risk factors identified in the bivariate analysis (prescription of ≥4 drugs, osteoporosis, diabetes mellitus and previous fracture).
136 cases and 544 controls were analysed. Adjusted OR (95% CI) for hip fracture associated with exposure to any antidepressants was 2.42 (1.24 to 4.73); for selective serotonin reuptake inhibitors (SSRIs) it was 3.52 (1.67 to 7.41), for non-selective monoamine reuptake inhibitors 1.07 (0.18 to 6.46) and for other antidepressants 0.82 (0.27 to 2.48). Sertraline (OR 3.88 (1.15 to 13.09)) was the only active principle with significant adjusted risk. When only exposures >6 months were considered, significant risks persisted for SSRIs (OR 2.64 (1.10 to 6.37)).
The results of this study are coincident with other studies in which SSRIs, but not other types of antidepressants, are associated with an increased risk of hip fracture in our setting.
描述在老年地中海人群中,不同抗抑郁药物暴露与髋部骨折之间的关联。
病例为 2010 年因非高能量创伤而入住我院急诊室的 50-95 岁髋部骨折患者。每位病例均从初级保健电子病历中匹配了 4 名对照,匹配因素包括年龄(±3 岁)、性别、在初级保健中心就诊日期(±1 个月)和初级保健中心。从处方记录中检索了 5 年内接受的药物治疗情况。通过条件逻辑回归计算了暴露与风险的比值比(OR)。OR 通过匹配变量和二变量分析中确定的显著危险因素(≥4 种药物处方、骨质疏松症、糖尿病和既往骨折)进行调整。
共分析了 136 例病例和 544 例对照。与任何抗抑郁药物暴露相关的髋部骨折的调整后 OR(95%CI)为 2.42(1.24-4.73);选择性 5-羟色胺再摄取抑制剂(SSRIs)为 3.52(1.67-7.41),非选择性单胺再摄取抑制剂为 1.07(0.18-6.46),其他抗抑郁药为 0.82(0.27-2.48)。舍曲林(OR 3.88(1.15-13.09))是唯一具有显著调整风险的活性成分。当仅考虑暴露时间>6 个月时,SSRIs 的风险仍然显著(OR 2.64(1.10-6.37))。
本研究结果与其他研究一致,即 SSRIs 而非其他类型的抗抑郁药与本研究中髋部骨折风险增加相关。